ERBB2 and congestive heart failure: In the light of the most current and longest trial evidence available to date, combining adjuvant trastuzumab with chemotherapy is able to gain the benefits of OS and DFS over the risk of CHF but not for LVEF decline when compared to chemotherapy alone in HER2-positive EBC women.